ArticleArchives of osteoporosis2026
High fracture risk in postmenopausal women established by FRAX, Garvan, and POL-RISK algorithms.
Article in Archives of osteoporosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study presents osteoporotic fracture risk in postmenopausal women established by FRAX, Garvan and POL-RISK algorithms for next 10 years. In studied group, a relatively high level of fracture risk was shown. These findings emphasize the importance of increasing treatment to reduce the expected rise in fracture rate in the future. PURPOSE: The aim of the study was to assess the 10-year osteoporotic fracture risk of postmenopausal women using the FRAX, Garvan, and POL-RISK algorithms and to compare those tools in terms of identification of high-risk subjects.
methodsThe study group consisted of 508 consecutive postmenopausal women recruited in three osteoporotic outpatient clinics. Mean age was 69.8 ± 7.5 years. Data on clinical risk factors were collected. Bone status was assessed at the hip using a Lunar Prodigy device. Fracture risk was established by FRAX, Garvan, and POL-RISK algorithms for the next 10 years.
resultsMean risk for major fractures for FRAX was 8.85 ± 5.43% and for any fractures for Garvan and POL-RISK 29.71 ± 20.53% and 28.1 ± 14.85%, respectively. Mean risk for hip fractures for FRAX was 3.23 ± 3.72% and 13.33 ± 18.30% for Garvan. For FRAX in 185 women (36.4%), hip fracture risk was high (≥ 3%) and in 119 (23.4%) very high ≥ 4.5% and high risk for major fracture was in 159 (31.3%) women (≥ 10%) and very high (≥ 15%) in 64 (12.6%) women. For therapeutic thresholds, high risk for FRAX major fracture, POL-RISK, and Garvan was noted in 316 (62.2%), 374 (73.5%) and 298 (58.5%) women, respectively. The results correlated for any (major) significantly between algorithms FRAX-Garvan r = 0.66, p < 0.001, FRAX-POL-RISK r = 0.60, p < 0.001, and Garvan-POL-RISK r = 0.93, p < 0.001. A stronger relationship was observed between Garvan and POL-RISK than between either of them and FRAX. FRAX hip risk correlated with Garvan hip risk r = 0.57, p < 0.001.
conclusionIn studied group, a relatively high level of fracture risk, especially for hip, was shown. Considering these findings, it is advisable to expand the population of postmenopausal women eligible for effective anti-osteoporotic therapy.
Indexed as
Identifiers
42665753What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.